The researchers identified new drug combination that reduces lung tumors in mice – the latest Lung cancer study review by BIOMEDICA CRO team
A new study led by Salk Institute Professor Reuben Shaw and former postdoctoral fellow Lillian Eichner, now an assistant professor at Northwestern University, revealed that FDA-approved trametinib and entinostat (which is currently in clinical trials) could be given in tandem to produce fewer and smaller tumors in mice with LKB1-mutated NSCLC.
“For non-small cell lung cancer cases with the LKB1 mutation, standard chemotherapy and immunotherapy treatments are not effective,” says Shaw, senior and co-corresponding author of the study and director of Salk’s Cancer Center. Thanks to the research team’s findings on the mouse models, there is hope now for a new way to target these cases using drugs that were FDA-approved or already in clinical trials.
“We thought the whole HDAC enzyme class was directly linked to the cause of LKB1 mutant Lung cancer. But we didn’t know the specific role of HDAC3 in lung tumor growth,” says first and co-corresponding author Eichner. “We’ve now shown that HDAC3 is essential in lung cancer and that it is a druggable vulnerability in therapeutic resistance.”
Please find more information on the Science Advances website, research article “HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non–small cell lung cancer”.
Human tissue, blood and other biosamples procurement for research by BIOMEDICA CRO – trusted biospecimens provider since 2017
The BIOMEDICA CRO team is aimed to organize the collection of various types of samples from healthy and diseased subjects following research needs. We are proud to participate in preclinical trials since 2017 and are ready to provide all our knowledge and experience to support your current needs by providing high-quality human biospecimens and associated patient data.
Our primary area is oncology studies, such as:
- Lung cancer (the majority of cases are NSCLC);
- Colorectal cancer (CRC);
- Kidney cancer;
- Breast cancer;
- Uterus/Endometrial/Cervical cancer, etc.
For the research needs we can collect tissue samples (tumor/NAT FFPE blocks, fresh frozen tissue samples, histological slides, and lymph nodes), blood samples (plasma, serum, buffy coat, PBMC) and other biofluids from cancer subjects.
In addition, we have contracted 50+ sites and departments with different disease areas.
Once you are close to conducting preclinical trials, we are ready to provide full support in line with good laboratory (GLP) and good clinical practices (GCP). By ordering biospecimens from BIOMEDICA CRO, you can be confident that you are investing in quality that will advance your understanding of diseases, lead to the development of new and more effective treatments, improve diagnosis, and advance personalized medicine.
Contact us today at office@biomedica-cro.com / LinkedIn to learn more about how we can support your research with the best biospecimens available. Our team is ready to join new projects and contribute to scientific cooperation!
